- Managing Director, Novartis Venture Fund
Steve Weinstein focuses on both medical device and bio/pharma investments for the fund. He brings significant operating and venture capital experience to Novartis’ investing efforts. Steve joined the Fund in 2006 as a Managing Director. He has led the investments and serves/d on the board of the following companies: Ablation Frontiers (acquired by Medtronic), Autonomic Technologies Inc.,Intersection Medical, Sonitus Medical, and Visiogen (acquired by Abbott).
Prior to Novartis, Steve was at Prism Venture Partners, where he focused on medical devices and served on the boards of iScienceInterventional, and Sensitech (acquired by Carrier/UTX). Prior to Prism, Steve was a Kauffman Fellow with Mid-Atlantic Venture Funds. He started his career as an entrepreneur and turnaround-CEO, raising angel funds to buy the assets of a defunct distribution business out of bankruptcy, and then rebuilding it over the next five years.
Steve holds an MBA with distinction from the University of Michigan Business School and a BS in mechanical engineering from Columbia University’s School of Engineering and Applied Science.Back to Innovation Advisory Board